Integra LifeSciences (IART) Financials

$16.08 -0.65 (-3.89%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$16.09 +0.01 (+0.06%)

As of 04/15/2025 06:34 PM Eastern

Annual Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Consolidated Net Income / (Loss)	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Net Income / (Loss) Continuing Operations	36	6.85	75	65	61	50	134	169	181	68	-6.94
Total Pre-Tax Income	46	61	90	11	57	60	94	215	214	81	-18
Total Operating Income	68	80	115	45	111	94	151	197	239	112	28
Total Gross Profit	494	556	643	753	901	953	851	945	970	885	882
Total Revenue	797	883	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611
Operating Revenue	797	883	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611
Total Cost of Revenue	303	327	349	436	571	565	521	598	587	657	728
Operating Cost of Revenue	303	327	349	436	571	565	521	598	587	657	728
Total Operating Expenses	426	477	528	708	790	859	700	747	731	773	854
Selling, General & Admin Expense	376	416	456	624	691	688	595	637	616	657	717
Research & Development Expense	44	51	58	63	78	144	77	93	101	104	115
Amortization Expense	6.81	9.95	14	20	21	27	28	17	14	12	21
Total Other Income / (Expense), net	-22	-19	-25	-33	-54	-34	-58	17	-25	-30	-47
Interest Expense	22	24	26	35	65	54	72	50	50	51	71
Interest & Investment Income	0.17	0.03	0.02	0.26	2.80	11	9.30	6.74	12	17	20
Other Income / (Expense), net	-0.49	4.59	0.85	1.35	8.29	9.52	4.43	61	13	3.72	3.94
Income Tax Expense	9.27	54	16	-53	-3.40	9.90	-40	46	33	13	-11
Basic Earnings per Share	$0.52	($0.05)	$1.00	$0.84	$0.73	$0.59	$1.58	$2.00	$2.18	$0.85	($0.09)
Weighted Average Basic Shares Outstanding	64.86M	68.99M	74.39M	76.90M	82.86M	85.64M	84.65M	84.70M	83.00M	80.09M	77.01M
Diluted Earnings per Share	$0.52	($0.05)	$0.94	$0.82	$0.72	$0.58	$1.57	$1.98	$2.16	$0.84	($0.09)
Weighted Average Diluted Shares Outstanding	65.92M	71.35M	79.19M	79.12M	84.00M	86.49M	85.23M	85.49M	83.52M	80.34M	77.01M
Weighted Average Basic & Diluted Shares Outstanding	32.40M	70.40M	74.60M	77.10M	83.30M	84.44M	84.37M	83.24M	81.64M	78.22M	77.22M

This table shows Integra LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	50	53	24	4.18	19	20	-3.28	-12	-11	19
Consolidated Net Income / (Loss)	50	53	24	4.18	19	20	-3.28	-12	-11	19
Net Income / (Loss) Continuing Operations	50	53	24	4.18	19	20	-3.28	-12	-11	19
Total Pre-Tax Income	59	64	30	3.82	19	29	-5.23	-15	-20	23
Total Operating Income	65	68	36	13	27	36	3.96	-3.03	-8.15	36
Total Gross Profit	237	250	233	207	218	226	207	226	200	249
Total Revenue	385	398	381	381	382	397	369	418	381	443
Operating Revenue	385	398	381	381	382	397	369	418	381	443
Total Cost of Revenue	148	148	148	174	164	171	162	192	181	194
Operating Cost of Revenue	148	148	148	174	164	171	162	192	181	194
Total Operating Expenses	172	182	196	195	192	190	203	229	208	213
Selling, General & Admin Expense	144	152	167	165	162	163	166	195	177	179
Research & Development Expense	25	27	27	27	27	24	27	30	27	31
Amortization Expense	3.14	3.54	3.11	3.03	3.21	3.03	10	3.71	3.76	3.72
Total Other Income / (Expense), net	-6.25	-3.63	-6.60	-8.68	-7.98	-7.19	-9.19	-12	-12	-13
Interest Expense	13	13	12	12	13	14	14	19	19	19
Interest & Investment Income	3.26	5.31	4.11	3.94	4.61	4.55	5.04	5.06	5.05	4.89
Other Income / (Expense), net	3.29	3.95	1.39	-0.16	0.47	2.01	-0.61	1.44	2.11	1.01
Income Tax Expense	8.88	11	5.55	-0.36	-0.89	9.02	-1.95	-2.78	-9.67	3.11
Basic Earnings per Share	$0.60	$0.65	$0.30	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25
Weighted Average Basic Shares Outstanding	83.04M	83.00M	81.87M	80.97M	79.69M	80.09M	77.74M	77.41M	76.45M	77.01M
Diluted Earnings per Share	$0.60	$0.63	$0.29	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25
Weighted Average Diluted Shares Outstanding	83.40M	83.52M	82.32M	81.15M	79.81M	80.34M	77.74M	77.41M	76.45M	77.01M
Weighted Average Basic & Diluted Shares Outstanding	83.52M	81.64M	81.90M	81.40M	78.18M	78.22M	78.80M	77.58M	77.16M	77.22M

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-49	-24	54	73	-31	60	271	43	-57	-180	-30
Net Cash From Operating Activities	84	105	116	115	200	231	204	312	264	140	129
Net Cash From Continuing Operating Activities	63	117	116	115	200	231	204	312	264	140	129
Net Income / (Loss) Continuing Operations	36	6.85	75	65	61	50	134	169	181	68	-6.94
Consolidated Net Income / (Loss)	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Depreciation Expense	46	59	73	89	111	109	116	120	118	124	141
Amortization Expense	2.57	2.26	2.53	2.72	6.27	5.39	12	-	6.85	6.16	5.59
Non-Cash Adjustments To Reconcile Net Income	23	60	-16	31	27	99	46	10	23	23	47
Changes in Operating Assets and Liabilities, net	-45	-11	-18	-73	-5.22	-32	-105	13	-64	-81	-58
Net Cash From Investing Activities	-363	-372	-43	-1,221	-50	-163	-68	-161	-59	-94	-391
Net Cash From Continuing Investing Activities	-360	-365	-43	-1,221	-50	-163	-68	-161	-59	-94	-391
Purchase of Property, Plant & Equipment	-38	-33	-47	-44	-78	-70	-39	-48	-42	-67	-104
Acquisitions	-321	-329	-	-1,242	0.00	-96	-25	-304	-56	0.00	-288
Purchase of Investments	-	-	-	-	0.00	1.58	-7.84	0.00	4.91	-27	-53
Sale of Property, Plant & Equipment	0.00	1.44	0.32	0.29	0.42	0.04	3.66	0.00	11	0.00	0.00
Divestitures	-	0.00	0.00	46	27	0.00	0.00	190	24	0.00	0.00
Sale and/or Maturity of Investments	-	0.00	0.00	17	0.91	0.75	-	0.08	0.00	0.00	55
Net Cash From Financing Activities	239	248	-15	1,169	-181	-8.77	122	-98	-252	-230	238
Net Cash From Continuing Financing Activities	239	295	-15	1,169	-181	-8.77	122	-98	-252	-230	238
Repayment of Debt	-199	-470	-701	-136	-665	-246	-465	-126	-149	-118	-187
Repurchase of Common Equity	-	-	-	-	0.00	0.00	-100	0.00	-125	-275	-52
Issuance of Debt	425	545	680	1,307	171	237	747	26	41	165	487
Other Financing Activities, net	12	0.72	5.63	-2.01	-37	0.43	-104	2.02	-19	-1.55	-9.04
Other Net Changes in Cash	-	-	-	11	-	0.07	-	-	-11	3.89	-6.46

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	65	-55	-149	1.83	-35	2.67	316	-377	-0.08	31
Net Cash From Operating Activities	68	85	26	28	27	59	16	40	22	51
Net Cash From Continuing Operating Activities	68	85	26	28	27	59	16	40	22	51
Net Income / (Loss) Continuing Operations	50	53	24	4.18	19	20	-3.28	-12	-11	19
Consolidated Net Income / (Loss)	50	53	24	4.18	19	20	-3.28	-12	-11	19
Depreciation Expense	29	29	31	31	31	31	31	37	36	38
Amortization Expense	1.75	1.70	1.89	1.42	1.42	1.43	1.40	1.46	1.34	1.40
Non-Cash Adjustments To Reconcile Net Income	10	-2.22	4.86	5.68	5.93	6.64	13	14	3.66	17
Changes in Operating Assets and Liabilities, net	-23	3.41	-36	-14	-31	-0.15	-26	0.44	-7.77	-24
Net Cash From Investing Activities	15	-55	-14	-16	-7.70	-57	-54	-322	-10	-4.25
Net Cash From Continuing Investing Activities	15	-55	-14	-16	-7.70	-57	-54	-322	-10	-4.25
Purchase of Property, Plant & Equipment	-9.16	-14	-14	-16	-13	-25	-15	-30	-30	-30
Acquisitions	-	-52	-	-	-	-	-	-	-	-5.77
Purchase of Investments	-	-	0.00	-	5.38	-33	-39	-10	-	-4.13
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	-	35
Net Cash From Financing Activities	-7.64	-98	-163	-11	-50	-6.89	359	-94	-20	-7.15
Net Cash From Continuing Financing Activities	-7.64	-98	-163	-11	-50	-6.89	359	-94	-20	-7.15
Repayment of Debt	-18	-108	-20	-17	-57	-25	-15	-91	-42	-40
Repurchase of Common Equity	-	-	-150	-	-125	-	0.00	-50	-	-2.47
Issuance of Debt	11	6.50	10	5.00	132	18	371	59	22	35
Other Financing Activities, net	-1.14	3.60	-2.91	1.01	0.44	-0.09	3.28	-12	-0.17	-0.14
Other Net Changes in Cash	-	12	0.94	-0.21	-4.87	8.04	-4.96	-1.13	7.75	-8.12

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,587	1,774	1,808	3,211	3,108	3,303	3,615	3,782	3,890	3,782	4,037
Total Current Assets	529	438	495	822	775	858	1,237	1,154	1,161	1,058	1,082
Cash & Equivalents	72	48	102	175	139	199	470	513	457	276	246
Short-Term Investments	-	-	-	-	-	-	-	-	0.00	33	27
Accounts Receivable	110	132	148	252	266	275	226	232	263	259	272
Inventories, net	189	211	217	296	280	316	310	317	325	390	429
Prepaid Expenses	28	43	28	99	90	68	69	91	86	67	77
Other Current Assets	-	-	-	-	-	-	-	-	31	33	30
Plant, Property, & Equipment, net	194	205	222	269	300	337	288	312	311	340	406
Total Noncurrent Assets	864	1,131	1,090	2,120	2,033	2,108	2,090	2,317	2,417	2,384	2,550
Goodwill	363	512	511	938	926	954	932	1,013	1,039	1,055	1,097
Intangible Assets	413	604	561	1,160	1,079	1,032	989	1,146	1,127	1,068	1,208
Noncurrent Deferred & Refundable Income Taxes	4.47	6.93	6.94	6.25	6.81	13	74	57	46	46	35
Other Noncurrent Operating Assets	10	7.49	12	16	20	109	95	101	205	214	211
Total Liabilities & Shareholders' Equity	1,587	1,774	1,808	3,211	3,108	3,303	3,615	3,782	3,890	3,782	4,037
Total Liabilities	883	1,023	968	2,249	1,732	1,887	2,100	2,098	2,085	2,194	2,492
Total Current Liabilities	126	139	124	349	263	331	401	340	321	307	922
Short-Term Debt	3.75	14	0.00	83	23	45	146	45	38	15	607
Accounts Payable	29	35	29	94	76	113	55	62	102	92	83
Accrued Expenses	40	39	35	88	85	77	94	120	80	101	122
Current Employee Benefit Liabilities	35	45	53	73	76	79	76	93	79	75	86
Other Current Liabilities	-	-	-	-	-	12	13	20	22	24	25
Total Noncurrent Liabilities	757	884	845	1,900	1,470	1,555	1,699	1,758	1,764	1,887	1,570
Long-Term Debt	626	700	665	1,781	1,332	1,303	1,408	1,501	1,405	1,485	1,196
Capital Lease Obligations	-	-	-	-	-	-	-	90	157	167	167
Noncurrent Deferred & Payable Income Tax Liabilities	100	155	149	65	58	37	16	46	63	35	61
Other Noncurrent Operating Liabilities	28	29	31	54	80	216	275	120	139	200	146
Total Equity & Noncontrolling Interests	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Total Preferred & Common Equity	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Common Stock	780	1,021	799	823	1,193	1,215	1,292	1,266	1,278	1,303	1,324
Retained Earnings	315	146	220	285	348	399	532	699	879	947	940
Treasury Stock	-367	-367	-123	-122	-121	-120	-235	-234	-363	-647	-691
Accumulated Other Comprehensive Income / (Loss)	-23	-48	-57	-24	-45	-76	-74	-45	10	-15	-28

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	3,807	3,742	3,778	3,739	4,078	4,074	4,066
Total Current Assets	1,196	1,029	1,051	1,027	1,416	1,112	1,100
Cash & Equivalents	512	307	309	274	592	215	215
Short-Term Investments	-	-	-	-	71	82	62
Accounts Receivable	248	254	259	256	241	271	248
Inventories, net	311	351	354	366	403	422	437
Prepaid Expenses	123	117	129	131	73	94	86
Other Current Assets	1.83	-	-	-	35	29	50
Plant, Property, & Equipment, net	301	315	318	319	345	374	391
Total Noncurrent Assets	2,310	2,398	2,409	2,393	2,317	2,589	2,575
Goodwill	978	1,042	1,043	1,036	1,040	1,105	1,117
Intangible Assets	1,054	1,109	1,094	1,067	1,023	1,220	1,210
Noncurrent Deferred & Refundable Income Taxes	52	45	56	56	34	46	49
Other Noncurrent Operating Assets	226	203	216	235	220	218	200
Total Liabilities & Shareholders' Equity	3,807	3,742	3,778	3,739	4,078	4,074	4,066
Total Liabilities	2,083	2,067	2,094	2,160	2,480	2,540	2,544
Total Current Liabilities	304	282	377	356	302	328	913
Short-Term Debt	56	0.00	96	85	19	24	602
Accounts Payable	81	113	100	94	94	107	78
Accrued Expenses	79	93	95	90	112	102	132
Current Deferred Revenue	6.36	-	-	-	-	-	9.99
Current Employee Benefit Liabilities	69	54	65	64	53	70	76
Other Current Liabilities	13	23	23	23	24	25	15
Total Noncurrent Liabilities	1,778	1,785	1,717	1,804	2,178	2,212	1,632
Long-Term Debt	1,487	1,440	1,333	1,420	1,837	1,801	1,205
Noncurrent Deferred & Payable Income Tax Liabilities	70	62	71	74	31	87	69
Other Noncurrent Operating Liabilities	221	127	153	142	140	155	358
Total Equity & Noncontrolling Interests	1,724	1,675	1,683	1,579	1,598	1,534	1,522
Total Preferred & Common Equity	1,724	1,675	1,683	1,579	1,598	1,534	1,522
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,724	1,675	1,683	1,579	1,598	1,534	1,522
Common Stock	1,269	1,246	1,285	1,263	1,311	1,302	1,318
Retained Earnings	826	903	908	927	944	931	920
Treasury Stock	-363	-482	-514	-613	-646	-681	-692
Accumulated Other Comprehensive Income / (Loss)	-7.44	7.07	4.83	1.75	-11	-19	-25

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.33%	10.80%	12.39%	19.77%	23.92%	3.06%	-9.60%	12.43%	0.99%	-1.03%	4.47%
EBITDA Growth	73.97%	24.86%	31.71%	-27.99%	71.45%	-7.68%	30.15%	33.20%	-0.39%	-34.99%	-26.98%
EBIT Growth	100.62%	24.95%	38.03%	-60.28%	158.48%	-13.42%	50.85%	65.81%	-2.62%	-54.19%	-71.92%
NOPAT Growth	30.32%	-83.37%	958.51%	167.83%	-53.86%	-33.39%	176.73%	-28.32%	29.83%	-53.79%	-78.66%
Net Income Growth	261.41%	-110.35%	2,218.90%	-13.17%	-6.09%	-17.43%	166.71%	26.28%	6.79%	-62.48%	-110.25%
EPS Growth	261.41%	-110.35%	2,218.90%	-12.77%	-12.20%	-19.44%	170.69%	26.11%	9.09%	-61.11%	-110.71%
Operating Cash Flow Growth	56.88%	25.48%	11.02%	-1.60%	74.33%	15.90%	-11.93%	53.28%	-15.35%	-47.08%	-7.55%
Free Cash Flow Firm Growth	-356.94%	-162.76%	135.50%	-1,035.49%	117.88%	-41.70%	222.20%	-161.03%	129.98%	58.00%	-386.75%
Invested Capital Growth	17.91%	27.88%	-0.79%	89.03%	-2.27%	-0.98%	-4.56%	14.66%	5.01%	-0.11%	10.07%
Revenue Q/Q Growth	9.84%	11.13%	1.48%	10.50%	1.01%	0.78%	-0.47%	1.11%	-0.48%	-0.06%	2.91%
EBITDA Q/Q Growth	-12.71%	1.85%	9.58%	-13.10%	11.57%	0.63%	5.78%	1.63%	4.12%	-11.72%	2.96%
EBIT Q/Q Growth	-33.50%	-3.82%	16.43%	-39.20%	24.82%	1.14%	12.21%	3.35%	3.85%	-22.64%	-4.23%
NOPAT Q/Q Growth	-37.89%	-43.89%	17.19%	244.04%	-50.58%	-17.25%	130.64%	-24.43%	2.43%	-24.94%	-1.46%
Net Income Q/Q Growth	11.09%	-163.99%	21.64%	33.12%	-24.02%	-16.36%	137.12%	-21.88%	4.37%	-32.83%	-6.11%
EPS Q/Q Growth	11.09%	-163.99%	21.64%	32.26%	-23.40%	-17.14%	134.33%	-21.74%	4.85%	-30.58%	-12.50%
Operating Cash Flow Q/Q Growth	18.70%	0.75%	-14.10%	4.58%	18.48%	25.14%	-4.19%	-3.40%	6.46%	-15.96%	-5.83%
Free Cash Flow Firm Q/Q Growth	26.97%	-52.85%	82.82%	-695.62%	123.51%	21.95%	5.26%	-73.87%	-58.35%	197.97%	-433.12%
Invested Capital Q/Q Growth	-5.41%	2.41%	-0.07%	65.44%	-0.20%	-1.54%	2.77%	3.78%	6.99%	-1.12%	6.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.98%	63.01%	64.81%	63.35%	61.19%	62.79%	62.03%	61.24%	62.29%	57.39%	54.77%
EBITDA Margin	14.61%	16.46%	19.29%	11.60%	16.05%	14.37%	20.70%	24.52%	24.18%	15.89%	11.10%
Operating Margin	8.52%	9.02%	11.63%	3.77%	7.54%	6.18%	11.03%	12.79%	15.34%	7.23%	1.76%
EBIT Margin	8.46%	9.54%	11.71%	3.88%	8.10%	6.81%	11.36%	16.75%	16.15%	7.48%	2.01%
Profit (Net Income) Margin	4.27%	-0.40%	7.52%	5.45%	4.13%	3.31%	9.76%	10.96%	11.59%	4.39%	-0.43%
Tax Burden Percent	74.63%	-5.80%	82.48%	568.67%	105.92%	83.52%	143.17%	78.76%	84.41%	83.56%	38.08%
Interest Burden Percent	67.64%	72.08%	77.81%	24.67%	48.12%	58.19%	60.02%	83.10%	85.02%	70.35%	-56.37%
Effective Tax Rate	20.35%	88.71%	17.52%	-468.67%	-5.92%	16.48%	-43.17%	21.24%	15.59%	16.44%	0.00%
Return on Invested Capital (ROIC)	5.29%	0.71%	6.76%	12.57%	4.49%	3.04%	8.64%	5.91%	7.01%	3.16%	0.64%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.67%	-1.64%	3.40%	-4.31%	0.58%	0.66%	0.69%	7.25%	5.14%	1.13%	-1.11%
Return on Net Nonoperating Assets (RNNOA)	-0.33%	-1.20%	2.62%	-5.38%	0.72%	0.56%	0.49%	4.66%	3.34%	0.83%	-1.09%
Return on Equity (ROE)	4.96%	-0.48%	9.37%	7.19%	5.20%	3.60%	9.13%	10.57%	10.35%	3.99%	-0.44%
Cash Return on Invested Capital (CROIC)	-11.15%	-23.76%	7.54%	-49.03%	6.78%	4.02%	13.31%	-7.75%	2.12%	3.27%	-8.94%
Operating Return on Assets (OROA)	4.85%	5.01%	6.49%	1.84%	3.78%	3.22%	4.50%	6.98%	6.56%	3.00%	0.83%
Return on Assets (ROA)	2.45%	-0.21%	4.16%	2.58%	1.92%	1.57%	3.87%	4.57%	4.71%	1.77%	-0.18%
Return on Common Equity (ROCE)	4.96%	-0.48%	9.37%	7.19%	5.20%	3.60%	9.13%	10.57%	10.35%	3.99%	-0.44%
Return on Equity Simple (ROE_SIMPLE)	4.83%	-0.47%	8.88%	6.73%	4.42%	3.54%	8.84%	10.04%	10.01%	4.27%	-0.45%
Net Operating Profit after Tax (NOPAT)	54	8.99	95	255	118	78	217	155	202	93	20
NOPAT Margin	6.78%	1.02%	9.59%	21.44%	7.98%	5.16%	15.80%	10.07%	12.95%	6.05%	1.23%
Net Nonoperating Expense Percent (NNEP)	5.96%	2.35%	3.36%	16.88%	3.91%	2.38%	7.95%	-1.34%	1.86%	2.03%	1.76%
Return On Investment Capital (ROIC_SIMPLE)	4.05%	0.61%	6.32%	9.02%	4.31%	2.83%	7.06%	4.68%	5.92%	2.86%	0.57%
Cost of Revenue to Revenue	38.02%	36.99%	35.19%	36.65%	38.81%	37.21%	37.97%	38.76%	37.71%	42.61%	45.23%
SG&A Expenses to Revenue	47.14%	47.10%	45.93%	52.52%	46.91%	45.31%	43.34%	41.33%	39.57%	42.60%	44.52%
R&D to Revenue	5.47%	5.77%	5.86%	5.34%	5.30%	9.52%	5.64%	6.03%	6.50%	6.76%	7.16%
Operating Expenses to Revenue	53.46%	53.99%	53.19%	59.58%	53.65%	56.61%	51.00%	48.46%	46.95%	50.16%	53.00%
Earnings before Interest and Taxes (EBIT)	67	84	116	46	119	103	156	258	252	115	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	116	145	191	138	236	218	284	378	377	245	179
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.52	3.34	3.82	3.90	2.79	3.53	3.61	3.37	2.60	2.14	1.13
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.23	2.84	3.23	3.16	2.61	3.30	3.99	3.68	3.01	2.21	1.09
Price to Earnings (P/E)	52.29	0.00	43.01	58.01	63.18	99.68	40.86	33.56	25.94	50.26	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.91%	0.00%	2.32%	1.72%	1.58%	1.00%	2.45%	2.98%	3.86%	1.99%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.11	2.24	2.69	2.05	1.95	2.40	2.68	2.42	1.98	1.62	1.06
Enterprise Value to Revenue (EV/Rev)	2.93	3.59	3.80	4.58	3.43	4.05	4.78	4.41	3.74	3.09	2.14
Enterprise Value to EBITDA (EV/EBITDA)	20.08	21.81	19.70	39.51	21.40	28.21	23.09	17.97	15.47	19.44	19.27
Enterprise Value to EBIT (EV/EBIT)	34.68	37.65	32.45	117.99	42.39	59.58	42.07	26.31	23.16	41.32	106.52
Enterprise Value to NOPAT (EV/NOPAT)	43.23	352.61	39.63	21.37	43.01	78.58	30.25	43.76	28.89	51.10	173.30
Enterprise Value to Operating Cash Flow (EV/OCF)	27.96	30.22	32.39	47.54	25.33	26.59	32.16	21.76	22.03	34.02	26.64
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	35.49	0.00	28.46	59.40	19.64	0.00	95.42	49.36	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.89	0.95	0.79	1.94	0.98	0.95	1.03	0.97	0.89	1.05	1.27
Long-Term Debt to Equity	0.89	0.93	0.79	1.85	0.97	0.92	0.93	0.94	0.87	1.04	0.88
Financial Leverage	0.49	0.73	0.77	1.25	1.24	0.85	0.71	0.64	0.65	0.74	0.97
Leverage Ratio	2.03	2.31	2.25	2.79	2.70	2.30	2.36	2.31	2.20	2.26	2.50
Compound Leverage Factor	1.37	1.66	1.75	0.69	1.30	1.34	1.42	1.92	1.87	1.59	-1.41
Debt to Total Capital	47.21%	48.74%	44.20%	65.95%	49.60%	48.76%	50.65%	49.27%	47.01%	51.21%	56.04%
Short-Term Debt to Total Capital	0.28%	0.98%	0.00%	2.93%	0.82%	1.63%	4.76%	1.35%	1.12%	0.45%	17.27%
Long-Term Debt to Total Capital	46.93%	47.76%	44.20%	63.02%	48.78%	47.13%	45.88%	47.92%	45.89%	50.76%	38.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.79%	51.26%	55.80%	34.05%	50.40%	51.24%	49.35%	50.73%	52.99%	48.79%	43.96%
Debt to EBITDA	5.41	4.92	3.47	13.52	5.73	6.18	5.48	4.33	4.25	6.80	11.02
Net Debt to EBITDA	4.80	4.56	2.94	12.26	5.14	5.27	3.82	2.97	3.04	5.54	9.49
Long-Term Debt to EBITDA	5.38	4.82	3.47	12.92	5.64	5.97	4.96	4.21	4.15	6.74	7.62
Debt to NOPAT	11.66	79.50	6.99	7.32	11.52	17.21	7.17	10.54	7.94	17.88	99.06
Net Debt to NOPAT	10.33	73.69	5.92	6.63	10.34	14.67	5.00	7.23	5.67	14.56	85.30
Long-Term Debt to NOPAT	11.59	77.90	6.99	6.99	11.33	16.64	6.50	10.25	7.75	17.73	68.53
Altman Z-Score	2.43	2.44	3.17	1.72	2.29	2.51	2.57	2.77	2.54	2.03	1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	3.15	4.01	2.36	2.95	2.59	3.09	3.39	3.62	3.45	1.17
Quick Ratio	1.45	1.30	2.02	1.22	1.54	1.43	1.73	2.19	2.24	1.85	0.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-114	-299	106	-994	178	104	334	-204	61	96	-277
Operating Cash Flow to CapEx	217.96%	327.92%	247.61%	265.09%	258.26%	333.00%	578.53%	650.63%	847.71%	209.31%	123.91%
Free Cash Flow to Firm to Interest Expense	-5.18	-12.72	4.12	-28.38	2.75	1.92	4.66	-4.04	1.23	1.88	-3.92
Operating Cash Flow to Interest Expense	3.80	4.46	4.51	3.27	3.09	4.29	2.85	6.20	5.33	2.72	1.83
Operating Cash Flow Less CapEx to Interest Expense	2.06	3.10	2.69	2.04	1.89	3.00	2.36	5.25	4.70	1.42	0.35
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.53	0.55	0.47	0.47	0.47	0.40	0.42	0.41	0.40	0.41
Accounts Receivable Turnover	6.97	7.28	7.08	5.94	5.69	5.61	5.48	6.75	6.29	5.90	6.06
Inventory Turnover	1.53	1.63	1.63	1.70	1.98	1.89	1.66	1.91	1.83	1.84	1.78
Fixed Asset Turnover	4.04	4.43	4.64	4.83	5.17	4.76	4.39	5.15	5.00	4.73	4.32
Accounts Payable Turnover	7.61	10.26	10.94	7.08	6.72	5.97	6.21	10.27	7.17	6.76	8.33
Days Sales Outstanding (DSO)	52.35	50.17	51.59	61.43	64.15	65.06	66.63	54.11	58.03	61.89	60.25
Days Inventory Outstanding (DIO)	238.59	223.87	224.12	215.22	184.16	192.75	219.41	191.57	199.47	198.44	205.11
Days Payable Outstanding (DPO)	47.96	35.57	33.37	51.55	54.29	61.13	58.76	35.55	50.94	54.02	43.80
Cash Conversion Cycle (CCC)	242.98	238.47	242.33	225.10	194.01	196.69	227.27	210.13	206.56	206.31	221.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,105	1,414	1,403	2,651	2,591	2,566	2,449	2,808	2,948	2,945	3,242
Invested Capital Turnover	0.78	0.70	0.70	0.59	0.56	0.59	0.55	0.59	0.54	0.52	0.52
Increase / (Decrease) in Invested Capital	168	308	-11	1,249	-60	-25	-117	359	141	-3.29	297
Enterprise Value (EV)	2,336	3,169	3,770	5,445	5,057	6,153	6,555	6,797	5,827	4,762	3,447
Market Capitalization	1,778	2,507	3,207	3,756	3,842	5,004	5,471	5,674	4,683	3,405	1,750
Book Value per Share	$21.48	$20.32	$22.46	$12.26	$16.15	$16.50	$17.98	$19.89	$21.60	$20.31	$20.03
Tangible Book Value per Share	($2.19)	($9.86)	($6.21)	($14.47)	($7.40)	($6.63)	($4.83)	($5.60)	($4.32)	($6.85)	($9.84)
Total Capital	1,334	1,466	1,505	2,826	2,730	2,765	3,069	3,321	3,405	3,254	3,515
Total Debt	630	714	665	1,864	1,354	1,348	1,554	1,637	1,601	1,666	1,970
Total Long-Term Debt	626	700	665	1,781	1,332	1,303	1,408	1,592	1,563	1,652	1,363
Net Debt	558	662	563	1,689	1,215	1,149	1,084	1,123	1,144	1,357	1,696
Capital Expenditures (CapEx)	38	32	47	43	77	70	35	48	31	67	104
Debt-free, Cash-free Net Working Capital (DFCFNWC)	335	262	270	381	396	373	512	345	422	456	493
Debt-free Net Working Capital (DFNWC)	407	314	372	556	535	572	982	859	879	766	767
Net Working Capital (NWC)	403	299	372	473	513	527	836	814	841	751	160
Net Nonoperating Expense (NNE)	20	13	21	190	57	28	83	-14	21	25	27
Net Nonoperating Obligations (NNO)	401	662	563	1,689	1,215	1,149	934	1,123	1,144	1,357	1,696
Total Depreciation and Amortization (D&A)	49	61	75	92	117	115	128	120	125	130	146
Debt-free, Cash-free Net Working Capital to Revenue	42.09%	29.63%	27.17%	32.07%	26.91%	24.58%	37.34%	22.38%	27.10%	29.61%	30.62%
Debt-free Net Working Capital to Revenue	51.09%	35.54%	37.45%	46.79%	36.34%	37.68%	71.61%	55.67%	56.41%	49.66%	47.60%
Net Working Capital to Revenue	50.62%	33.91%	37.45%	39.83%	34.81%	34.72%	60.95%	52.75%	53.96%	48.72%	9.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.47	($0.05)	$1.00	$0.84	$0.73	$0.59	$1.58	$2.00	$2.18	$0.85	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	71.72M	68.99M	74.39M	76.90M	82.86M	85.64M	84.65M	84.70M	83.00M	80.09M	77.01M
Adjusted Diluted Earnings per Share	$0.47	($0.05)	$0.94	$0.82	$0.72	$0.58	$1.57	$1.98	$2.16	$0.84	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	72.89M	71.35M	79.19M	79.12M	84.00M	86.49M	85.23M	85.49M	83.52M	80.34M	77.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	72.48M	74.00M	74.82M	78.49M	85.23M	84.44M	84.37M	83.24M	81.64M	78.22M	77.22M
Normalized Net Operating Profit after Tax (NOPAT)	54	56	95	31	78	78	106	155	202	93	20
Normalized NOPAT Margin	6.78%	6.31%	9.59%	2.64%	5.28%	5.16%	7.72%	10.07%	12.95%	6.05%	1.23%
Pre Tax Income Margin	5.72%	6.87%	9.11%	0.96%	3.90%	3.96%	6.82%	13.92%	13.73%	5.26%	-1.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.07	3.58	4.50	1.32	1.84	1.91	2.18	5.13	5.07	2.24	0.46
NOPAT to Interest Expense	2.46	0.38	3.69	7.28	1.82	1.45	3.03	3.08	4.07	1.81	0.28
EBIT Less CapEx to Interest Expense	1.32	2.22	2.68	0.08	0.65	0.63	1.68	4.17	4.44	0.94	-1.02
NOPAT Less CapEx to Interest Expense	0.72	-0.98	1.86	6.04	0.62	0.16	2.54	2.13	3.44	0.51	-1.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	74.69%	0.00%	69.23%	405.96%	-755.63%

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.43%	-1.85%	1.12%	-4.16%	-0.72%	-0.25%	-3.14%	9.68%	-0.42%	11.49%
EBITDA Growth	6.99%	10.48%	-12.63%	-52.11%	-40.70%	-31.57%	-50.12%	-17.83%	-47.06%	7.30%
EBIT Growth	11.68%	14.92%	-23.84%	-80.03%	-60.40%	-46.99%	-91.12%	-112.89%	-122.31%	-3.75%
NOPAT Growth	14.96%	9.64%	-23.38%	-73.68%	-49.55%	-55.71%	-90.63%	-115.50%	-120.48%	23.98%
Net Income Growth	15.47%	16.66%	-26.37%	-90.66%	-60.94%	-62.54%	-113.54%	-396.41%	-154.85%	-2.02%
EPS Growth	17.65%	18.87%	-25.64%	-90.74%	-60.00%	-58.73%	-113.79%	-420.00%	-158.33%	-3.85%
Operating Cash Flow Growth	-17.48%	23.18%	-41.02%	-57.46%	-60.81%	-31.15%	-39.76%	42.87%	-16.01%	-13.63%
Free Cash Flow Firm Growth	101.80%	72.51%	-171.52%	-2,266.04%	-4,040.08%	133.15%	103.36%	-47.53%	60.07%	-1,047.17%
Invested Capital Growth	1.86%	5.01%	7.59%	7.16%	8.08%	-0.11%	-0.11%	9.10%	2.42%	10.07%
Revenue Q/Q Growth	-3.17%	3.33%	-4.32%	0.11%	0.30%	3.82%	-7.09%	13.37%	-8.93%	16.23%
EBITDA Q/Q Growth	6.91%	3.45%	-31.25%	-37.01%	32.38%	19.38%	-49.89%	3.76%	-14.70%	141.92%
EBIT Q/Q Growth	10.50%	5.05%	-47.39%	-67.31%	119.16%	40.63%	-91.19%	-147.47%	-279.27%	706.67%
NOPAT Q/Q Growth	6.22%	1.30%	-47.09%	-53.78%	103.65%	-11.08%	-88.80%	-176.41%	-169.07%	638.42%
Net Income Q/Q Growth	11.45%	6.07%	-54.24%	-82.73%	365.99%	1.73%	-116.54%	-277.99%	13.76%	281.71%
EPS Q/Q Growth	11.11%	5.00%	-53.97%	-82.76%	380.00%	8.33%	-115.38%	-300.00%	12.50%	278.57%
Operating Cash Flow Q/Q Growth	2.76%	24.92%	-69.35%	8.12%	-5.34%	119.46%	-73.18%	156.42%	-44.35%	125.66%
Free Cash Flow Firm Q/Q Growth	-41.85%	-1,812.72%	-112.08%	-2.56%	-5.77%	114.41%	-78.48%	-4,598.95%	71.37%	-241.77%
Invested Capital Q/Q Growth	-0.32%	6.99%	0.53%	-0.06%	0.54%	-1.12%	0.53%	9.16%	-5.62%	6.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.46%	62.83%	61.15%	54.30%	57.10%	57.05%	56.07%	54.02%	52.58%	56.27%
EBITDA Margin	25.85%	25.88%	18.59%	11.70%	15.44%	17.75%	9.57%	8.76%	8.21%	17.08%
Operating Margin	16.89%	17.04%	9.55%	3.28%	6.95%	9.08%	1.07%	-0.72%	-2.14%	8.05%
EBIT Margin	17.74%	18.04%	9.92%	3.24%	7.08%	9.59%	0.91%	-0.38%	-1.59%	8.28%
Profit (Net Income) Margin	12.96%	13.30%	6.36%	1.10%	5.10%	5.00%	-0.89%	-2.97%	-2.81%	4.39%
Tax Burden Percent	84.90%	82.46%	81.36%	109.41%	104.77%	68.73%	62.73%	81.67%	52.52%	86.22%
Interest Burden Percent	86.03%	89.44%	78.84%	30.97%	68.76%	75.82%	-155.93%	953.83%	337.23%	61.53%
Effective Tax Rate	15.10%	17.54%	18.64%	-9.41%	-4.77%	31.27%	0.00%	0.00%	0.00%	13.78%
Return on Invested Capital (ROIC)	8.22%	7.61%	4.24%	1.94%	3.92%	3.26%	0.39%	-0.26%	-0.78%	3.61%
ROIC Less NNEP Spread (ROIC-NNEP)	7.71%	7.34%	3.80%	1.14%	3.23%	2.87%	-0.07%	-0.95%	-1.12%	2.87%
Return on Net Nonoperating Assets (RNNOA)	4.84%	4.77%	2.81%	0.81%	2.38%	2.12%	-0.06%	-0.88%	-1.06%	2.80%
Return on Equity (ROE)	13.06%	12.38%	7.05%	2.75%	6.30%	5.38%	0.33%	-1.13%	-1.83%	6.41%
Cash Return on Invested Capital (CROIC)	5.37%	2.12%	-0.58%	-1.59%	-3.43%	3.27%	2.44%	-6.91%	-1.72%	-8.94%
Operating Return on Assets (OROA)	7.33%	7.32%	4.18%	1.33%	2.89%	3.85%	0.36%	-0.15%	-0.64%	3.41%
Return on Assets (ROA)	5.35%	5.40%	2.68%	0.45%	2.08%	2.01%	-0.35%	-1.18%	-1.13%	1.81%
Return on Common Equity (ROCE)	13.06%	12.38%	7.05%	2.75%	6.30%	5.38%	0.33%	-1.13%	-1.83%	6.41%
Return on Equity Simple (ROE_SIMPLE)	10.03%	0.00%	10.26%	7.80%	6.39%	0.00%	2.52%	1.54%	-0.43%	0.00%
Net Operating Profit after Tax (NOPAT)	55	56	30	14	28	25	2.77	-2.12	-5.71	31
NOPAT Margin	14.34%	14.05%	7.77%	3.59%	7.29%	6.24%	0.75%	-0.51%	-1.50%	6.94%
Net Nonoperating Expense Percent (NNEP)	0.50%	0.26%	0.44%	0.80%	0.69%	0.40%	0.46%	0.69%	0.34%	0.74%
Return On Investment Capital (ROIC_SIMPLE)	1.69%	1.64%	0.90%	0.42%	0.86%	0.76%	0.08%	-0.06%	-0.17%	0.87%
Cost of Revenue to Revenue	38.54%	37.17%	38.85%	45.70%	42.90%	42.95%	43.93%	45.98%	47.42%	43.73%
SG&A Expenses to Revenue	37.34%	38.17%	43.76%	43.25%	42.35%	41.09%	44.95%	46.74%	46.53%	40.33%
R&D to Revenue	6.42%	6.73%	7.02%	6.97%	6.95%	6.12%	7.31%	7.12%	7.20%	7.05%
Operating Expenses to Revenue	44.57%	45.79%	51.59%	51.02%	50.14%	47.97%	55.00%	54.75%	54.72%	48.22%
Earnings before Interest and Taxes (EBIT)	68	72	38	12	27	38	3.35	-1.59	-6.04	37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	100	103	71	45	59	70	35	37	31	76
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.05	2.60	2.80	2.00	1.97	2.14	1.73	1.50	0.93	1.13
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.26	3.01	3.00	2.18	2.02	2.21	1.81	1.47	0.90	1.09
Price to Earnings (P/E)	20.45	25.94	27.27	25.66	30.83	50.26	68.88	97.10	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.89%	3.86%	3.67%	3.90%	3.24%	1.99%	1.45%	1.03%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.66	1.98	2.02	1.57	1.51	1.62	1.40	1.24	0.96	1.06
Enterprise Value to Revenue (EV/Rev)	2.92	3.74	3.83	3.01	2.92	3.09	2.70	2.55	1.88	2.14
Enterprise Value to EBITDA (EV/EBITDA)	12.63	15.47	16.31	14.62	16.25	19.44	19.74	19.82	16.92	19.27
Enterprise Value to EBIT (EV/EBIT)	18.86	23.16	24.93	24.43	30.26	41.32	51.15	59.72	86.98	106.52
Enterprise Value to NOPAT (EV/NOPAT)	23.21	28.89	31.01	30.51	36.31	51.10	59.83	71.87	145.61	173.30
Enterprise Value to Operating Cash Flow (EV/OCF)	18.39	22.03	24.26	22.34	27.07	34.02	31.91	28.19	21.39	26.64
Enterprise Value to Free Cash Flow (EV/FCFF)	31.16	95.42	0.00	0.00	0.00	49.36	57.13	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.90	0.89	0.95	0.94	1.06	1.05	1.27	1.30	1.19	1.27
Long-Term Debt to Equity	0.86	0.87	0.95	0.89	1.01	1.04	1.26	1.28	0.79	0.88
Financial Leverage	0.63	0.65	0.74	0.71	0.74	0.74	0.81	0.93	0.94	0.97
Leverage Ratio	2.26	2.20	2.25	2.25	2.28	2.26	2.39	2.44	2.52	2.50
Compound Leverage Factor	1.94	1.97	1.78	0.70	1.57	1.71	-3.73	23.28	8.49	1.54
Debt to Total Capital	47.23%	47.01%	48.80%	48.55%	51.44%	51.21%	55.91%	56.53%	54.28%	56.04%
Short-Term Debt to Total Capital	1.72%	1.12%	0.00%	2.92%	2.63%	0.45%	0.53%	0.69%	18.07%	17.27%
Long-Term Debt to Total Capital	45.51%	45.89%	48.80%	45.63%	48.82%	50.76%	55.37%	55.84%	36.21%	38.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.77%	52.99%	51.20%	51.45%	48.56%	48.79%	44.09%	43.47%	45.72%	43.96%
Debt to EBITDA	4.27	4.25	4.36	5.00	6.03	6.80	9.67	9.90	10.40	11.02
Net Debt to EBITDA	2.85	3.04	3.52	4.02	5.04	5.54	6.51	8.43	8.80	9.49
Long-Term Debt to EBITDA	4.11	4.15	4.36	4.70	5.72	6.74	9.58	9.78	6.94	7.62
Debt to NOPAT	7.84	7.94	8.28	10.43	13.48	17.88	29.32	35.89	89.51	99.06
Net Debt to NOPAT	5.24	5.67	6.69	8.40	11.27	14.56	19.72	30.55	75.76	85.30
Long-Term Debt to NOPAT	7.55	7.75	8.28	9.80	12.79	17.73	29.04	35.46	59.71	68.53
Altman Z-Score	2.07	2.38	2.39	1.94	1.86	1.96	1.70	1.48	1.08	1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.93	3.62	3.65	2.78	2.89	3.45	4.68	3.39	1.20	1.17
Quick Ratio	2.50	2.24	1.99	1.50	1.49	1.85	2.99	1.73	0.58	0.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4.94	-85	-180	-184	-195	28	6.04	-272	-78	-266
Operating Cash Flow to CapEx	746.18%	590.30%	190.86%	181.88%	204.69%	239.45%	101.88%	136.00%	75.85%	171.42%
Free Cash Flow to Firm to Interest Expense	0.39	-6.57	-14.84	-14.77	-14.91	2.04	0.44	-14.57	-4.02	-14.00
Operating Cash Flow to Interest Expense	5.33	6.62	2.16	2.27	2.05	4.27	1.16	2.17	1.16	2.67
Operating Cash Flow Less CapEx to Interest Expense	4.62	5.50	1.03	1.02	1.05	2.49	0.02	0.57	-0.37	1.11
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.41	0.42	0.41	0.41	0.40	0.39	0.40	0.40	0.41
Accounts Receivable Turnover	6.65	6.29	6.40	6.23	6.11	5.90	6.18	5.91	6.20	6.06
Inventory Turnover	1.87	1.83	1.75	1.83	1.87	1.84	1.78	1.78	1.76	1.78
Fixed Asset Turnover	5.26	5.00	5.00	4.99	4.98	4.73	4.63	4.53	4.41	4.32
Accounts Payable Turnover	8.49	7.17	5.89	7.31	7.28	6.76	6.48	6.65	8.24	8.33
Days Sales Outstanding (DSO)	54.86	58.03	57.02	58.58	59.69	61.89	59.07	61.72	58.84	60.25
Days Inventory Outstanding (DIO)	195.54	199.47	209.14	198.99	194.90	198.44	205.29	205.59	207.79	205.11
Days Payable Outstanding (DPO)	42.99	50.94	61.93	49.94	50.15	54.02	56.36	54.90	44.29	43.80
Cash Conversion Cycle (CCC)	207.41	206.56	204.23	207.64	204.44	206.31	208.01	212.41	222.33	221.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,756	2,948	2,964	2,963	2,979	2,945	2,961	3,232	3,051	3,242
Invested Capital Turnover	0.57	0.54	0.55	0.54	0.54	0.52	0.52	0.51	0.52	0.52
Increase / (Decrease) in Invested Capital	50	141	209	198	223	-3.29	-3.26	270	72	297
Enterprise Value (EV)	4,569	5,827	5,976	4,648	4,508	4,762	4,134	3,994	2,939	3,447
Market Capitalization	3,537	4,683	4,687	3,369	3,109	3,405	2,771	2,296	1,410	1,750
Book Value per Share	$20.65	$21.60	$20.52	$20.55	$19.40	$20.31	$20.56	$19.47	$19.61	$20.03
Tangible Book Value per Share	($3.68)	($4.32)	($5.82)	($5.54)	($6.44)	($6.85)	($5.98)	($10.03)	($10.37)	($9.84)
Total Capital	3,268	3,405	3,272	3,272	3,252	3,254	3,624	3,529	3,328	3,515
Total Debt	1,543	1,601	1,597	1,589	1,673	1,666	2,026	1,995	1,807	1,970
Total Long-Term Debt	1,487	1,563	1,597	1,493	1,588	1,652	2,007	1,971	1,205	1,363
Net Debt	1,031	1,144	1,289	1,279	1,399	1,357	1,363	1,698	1,529	1,696
Capital Expenditures (CapEx)	9.16	14	14	16	13	25	15	30	30	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	436	422	440	460	483	456	470	511	511	493
Debt-free Net Working Capital (DFNWC)	948	879	747	769	757	766	1,133	808	788	767
Net Working Capital (NWC)	892	841	747	674	672	751	1,113	784	187	160
Net Nonoperating Expense (NNE)	5.31	2.99	5.37	9.50	8.36	4.94	6.06	10	4.99	11
Net Nonoperating Obligations (NNO)	1,031	1,144	1,289	1,279	1,399	1,357	1,363	1,698	1,529	1,696
Total Depreciation and Amortization (D&A)	31	31	33	32	32	32	32	38	37	39
Debt-free, Cash-free Net Working Capital to Revenue	27.88%	27.10%	28.16%	29.78%	31.32%	29.61%	30.70%	32.64%	32.64%	30.62%
Debt-free Net Working Capital to Revenue	60.58%	56.41%	47.84%	49.79%	49.07%	49.66%	74.05%	51.59%	50.38%	47.60%
Net Working Capital to Revenue	56.99%	53.96%	47.84%	43.60%	43.53%	48.72%	72.78%	50.05%	11.95%	9.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.60	$0.65	$0.30	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25
Adjusted Weighted Average Basic Shares Outstanding	83.04M	83.00M	81.87M	80.97M	79.69M	80.09M	77.74M	77.41M	76.45M	77.01M
Adjusted Diluted Earnings per Share	$0.60	$0.63	$0.29	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25
Adjusted Weighted Average Diluted Shares Outstanding	83.40M	83.52M	82.32M	81.15M	79.81M	80.34M	77.74M	77.41M	76.45M	77.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	83.52M	81.64M	81.90M	81.40M	78.18M	78.22M	78.80M	77.58M	77.16M	77.22M
Normalized Net Operating Profit after Tax (NOPAT)	55	56	30	8.75	19	25	2.77	-2.12	-5.71	31
Normalized NOPAT Margin	14.34%	14.05%	7.77%	2.30%	4.87%	6.24%	0.75%	-0.51%	-1.50%	6.94%
Pre Tax Income Margin	15.26%	16.13%	7.82%	1.00%	4.87%	7.27%	-1.42%	-3.63%	-5.35%	5.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.34	5.57	3.12	0.99	2.07	2.77	0.25	-0.09	-0.31	1.93
NOPAT to Interest Expense	4.31	4.34	2.45	1.10	2.13	1.80	0.20	-0.11	-0.29	1.62
EBIT Less CapEx to Interest Expense	4.62	4.45	1.99	-0.26	1.07	0.98	-0.89	-1.68	-1.84	0.37
NOPAT Less CapEx to Interest Expense	3.60	3.22	1.31	-0.15	1.13	0.02	-0.93	-1.71	-1.82	0.06
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	72.26%	69.23%	87.27%	114.27%	272.67%	405.96%	310.68%	740.02%	-764.06%	-755.63%

Frequently Asked Questions About Integra LifeSciences' Financials

When does Integra LifeSciences's fiscal year end?

According to the most recent income statement we have on file, Integra LifeSciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Integra LifeSciences' net income changed over the last 10 years?

Integra LifeSciences' net income appears to be on an upward trend, with a most recent value of -$6.94 million in 2024, falling from $34.00 million in 2014. The previous period was $67.74 million in 2023.

What is Integra LifeSciences's operating income?

Integra LifeSciences's total operating income in 2024 was $28.41 million, based on the following breakdown:

Total Gross Profit: $882.06 million
Total Operating Expenses: $853.65 million

How has Integra LifeSciences revenue changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' total revenue changed from $796.72 million in 2014 to $1.61 billion in 2024, a change of 102.1%.

How much debt does Integra LifeSciences have?

Integra LifeSciences' total liabilities were at $2.49 billion at the end of 2024, a 13.6% increase from 2023, and a 182.2% increase since 2014.

How much cash does Integra LifeSciences have?

In the past 10 years, Integra LifeSciences' cash and equivalents has ranged from $48.13 million in 2015 to $513.45 million in 2021, and is currently $246.38 million as of their latest financial filing in 2024.

How has Integra LifeSciences' book value per share changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' book value per share changed from 21.48 in 2014 to 20.03 in 2024, a change of -6.8%.

Remove Ads

Related Companies

This page (NASDAQ:IART) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Financials

Frequently Asked Questions About Integra LifeSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integra LifeSciences (IART) Financials

Annual Income Statements for Integra LifeSciences

Quarterly Income Statements for Integra LifeSciences

Annual Cash Flow Statements for Integra LifeSciences

Quarterly Cash Flow Statements for Integra LifeSciences

Annual Balance Sheets for Integra LifeSciences

Quarterly Balance Sheets for Integra LifeSciences

Annual Metrics and Ratios for Integra LifeSciences

Quarterly Metrics and Ratios for Integra LifeSciences

Frequently Asked Questions About Integra LifeSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools